SHTN1
Shootin-1
Protein Summary
Involved in the generation of internal asymmetric signals required for neuronal polarization and neurite outgrowth. Mediates netrin-1-induced F-actin-substrate coupling or 'clutch engagement' within the axon growth cone through activation of CDC42, RAC1 and PAK1-dependent signaling pathway, thereby converting the F-actin retrograde flow into traction forces, concomitantly with filopodium extension and axon outgrowth. Plays a role in cytoskeletal organization by regulating the subcellular localization of phosphoinositide 3-kinase (PI3K) activity at the axonal growth cone. Plays also a role in regenerative neurite outgrowth. In the developing cortex, cooperates with KIF20B to promote both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex. Involved in the accumulation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the growth cone of primary hippocampal neurons.
- ENST00000260777
- ENSP00000260777
- ENSG00000187164
- ENST00000355371
- ENSP00000347532
- ENST00000392901
- ENSP00000376635
- ENST00000392903
- ENSP00000376636
- ENST00000615301
- ENSP00000480109
- KIAA1598
- KIAA1598
- shootin-1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0 | ||
biological term | 0 | ||
cell line | 0 | ||
cell type or tissue | 0 | ||
cellular component | 0 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 20.53 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 35 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 20.53 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 35 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0